April 2014 HSCI Community Newsletter
The Harvard Stem Cell Matrix
Upcoming Events
 Nervous System Diseases
Program Webinar
April 17, 12:00 PM-1:00 PM

HSCI Technology Series
Part 1: Imaging Technology
May 5, 12:00 PM-1:00 PM
Webinar option available

 Cancer Program Meeting
May 7, 12:00 PM-2:00 PM

HSCI Retreat: The Future is Now
May 23, 8:30 AM-6:00 PM
Register - Present a Poster
iPS core discount:
Quantity discounts now available for derivation services

HSCI call for proposals
- Deadline May 1
P01 Pilot Grants 2014

ReproCell's Innovative Research Grant Program - Deadline June 30
Faculty Staff Assistant
Massachusetts General Hospital - Center for Regenerative Medicine

Research Fellow
Sherwood Lab - Brigham and Women's Hospital

Research Technician I
Goessling Lab - Brigham and Women's Hospital

Senior Stem Cell Research Tech
Jovinge Group
Media Mentions
The Stem Cell Podcast
Leonard Zon, MD, talks about his work using zebrafish as a model to study cancer and melanoma.

A reporter examines the lack of standardization for commercial stem cell line production.
Patient stem cells help uncover a common problem in ALS
Kevin Eggan PhD, and Clifford Woolf, MD, PhD, collaborate to find FDA-approved drug that will go directly to clinical trials
HSCI scientists have discovered that a recently approved medication for epilepsy may possibly be a meaningful treatment for amyotrophic lateral sclerosis (ALS)--Lou Gehrig's disease, a uniformly fatal neurodegenerative disorder. The researchers are now collaborating with Massachusetts General Hospital to design an initial clinical trial testing the safety of the treatment in ALS patients.


The work, laid out in two related papers in the April 3 online editions of Cell Stem Cell and Cell Reports, is the long-term fruition of studies by Harvard Stem Cell Institute (HSCI) Principal Faculty member Kevin Eggan, PhD, who, in a 2008 Science paper first raised the possibility of using ALS patient-derived stem cells to better understand the disease and identify therapeutic targets for new drugs. Continue reading

Meet HSCRB's executive director
Willy Lensch, PhD, talks about his favorite part of being in the lab and why Harvard's stem cell programs are unique

Last fall, M. William "Willy" Lensch, PhD, the long-time director of HSCI's Internship Program, was named executive director of the Harvard Department of Stem Cell and Regenerative Biology (HSCRB).  


Lensch brings to the position experience directing the day-to-day operations of one of Boston Children's Hospital's largest laboratories, that of HSCI Executive Committee member George Daley, MD, PhD, as well as a personal interest in higher education. He spoke with HSCI about his new role: Read the interview

People News
Research Updates